Search results for "DP"

showing 10 items of 10968 documents

Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study)

2018

[Background]: While nutritional interventions with prebiotics and probiotics seem to exert immunological effects, their clinical implications in human immunodeficiency virus (HIV)–infected subjects initiating antiretroviral therapy (ART) at advanced HIV disease remain unclear.

0301 basic medicineMicrobiology (medical)medicine.medical_specialtySynbioticsCD4 T cellsPlaceboGastroenterologylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialAcquired immunodeficiency syndrome (AIDS)lawInternal medicinemedicineImmunoactivation030212 general & internal medicineYoung adultAdverse effectInflammationbusiness.industrySurrogate endpointMicrobiotaProbioticsvirus diseasesmedicine.diseaseClinical trial030104 developmental biologyInfectious DiseasesbusinessClinical Infectious Diseases
researchProduct

The role of mitochondrial reactive oxygen species, NO and H2S in ischaemia/reperfusion injury and cardioprotection

2020

Redox signalling in mitochondria plays an important role in myocardial ischaemia/reperfusion (I/R) injury and in cardioprotection. Reactive oxygen and nitrogen species (ROS/RNS) modify cellular structures and functions by means of covalent changes in proteins including among others S‐nitros(yl)ation by nitric oxide (NO) and its derivatives, and S‐sulphydration by hydrogen sulphide (H2S). Many enzymes are involved in the mitochondrial formation and handling of ROS, NO and H2S under physiological and pathological conditions. In particular, the balance between formation and removal of reactive species is impaired during I/R favouring their accumulation. Therefore, various interventions aimed a…

0301 basic medicineMitochondrial ROSIschemiaEndogenyheartMitochondrionRedoxNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicinenitric oxidemedicinechemistry.chemical_classificationCardioprotectionreactive oxygen speciesReactive oxygen speciesVDP::Medisinske Fag: 700::Basale medisinske odontologiske og veterinærmedisinske fag: 710Cell Biologymedicine.diseaseVDP::Medical disciplines: 700::Basic medical dental and veterinary science disciplines: 710Cell biologyreperfusionmitochondria030104 developmental biologychemistry030220 oncology & carcinogenesiscardioprotectionMolecular Medicineischaemiahydrogen sulphidecardioprotection; heart; hydrogen sulphide; ischaemia; mitochondria; nitric oxide; reactive oxygen species; reperfusion
researchProduct

Molecular docking-based design and development of a highly selective probe substrate for UDP-glucuronosyltransferase 1A10

2018

Intestinal and hepatic glucuronidation by the UDP-glucuronosyltransferases (UGTs) greatly affect the bioavailability of phenolic compounds. UGT1A10 catalyzes glucuronidation reactions in the intestine, but not in the liver. Here, our aim was to develop selective, fluorescent substrates to easily elucidate UGT1A10 function. To this end, homology models were constructed and used to design new substrates, and subsequently, six novel C3-substituted (4-fluorophenyl, 4-hydroxyphenyl, 4-methoxyphenyl, 4-(dimethylamino)phenyl, 4-methylphenyl, or triazole) 7-hydroxycoumarin derivatives were synthesized from inexpensive starting materials. All tested compounds could be glucuronidated to nonfluorescen…

0301 basic medicineMutantGlucuronidationPharmaceutical ScienceUGT1A10030226 pharmacology & pharmacySubstrate Specificity7-hydroxycoumarin derivativechemistry.chemical_compound0302 clinical medicineDrug DiscoveryCRYSTAL-STRUCTUREGlucuronosyltransferaseta116ta317AFFINITYchemistry.chemical_classificationChemistry3. Good healthMolecular ImagingMolecular Docking Simulation7-hydroxycoumarin317 Pharmacyin silicoMolecular MedicinefluorescenceUDP-glucuronosyltransferaseEXPRESSIONENZYMEStereochemistryIn silicoKineticsFLUORESCENT-PROBETriazoleta311103 medical and health sciencesGlucuronidesMicrosomesXENOBIOTICSHumansUmbelliferonesFluorescent DyesGLUCURONIDATIONta1182glucuronidationfluoresenssiSubstrate (chemistry)drug metabolism030104 developmental biologyEnzymeDRUG-METABOLISMDrug DesignMolecular ProbesMutationMutagenesis Site-DirectedORAL BIOAVAILABILITYDrug metabolism
researchProduct

Redox regulation of cardiovascular inflammation – Immunomodulatory function of mitochondrial and Nox-derived reactive oxygen and nitrogen species

2017

Oxidative stress is a major hallmark of cardiovascular diseases although a causal link was so far not proven by large clinical trials. However, there is a close association between oxidative stress and inflammation and increasing evidence for a causal role of (low-grade) inflammation for the onset and progression of cardiovascular diseases, which may serve as the missing link between oxidative stress and cardiovascular morbidity and mortality. With the present review we would like to highlight the multiple redox regulated pathways in inflammation, discuss the sources of reactive oxygen and nitrogen species that are of interest for these processes and finally discuss the importance of angiot…

0301 basic medicineNeutrophilsInflammationmedicine.disease_causeCardiovascular SystemExtracellular TrapsBiochemistrystat03 medical and health scienceschemistry.chemical_compoundPhysiology (medical)medicineHumansEndothelial dysfunctionInflammationMitoQChemistryAngiotensin IIEndothelial CellsNADPH OxidasesNF-κBmedicine.diseaseReactive Nitrogen SpeciesAngiotensin IIMitochondriaOxidative Stress030104 developmental biologyGene Expression RegulationCardiovascular DiseasesTRIFImmunologymedicine.symptomReactive Oxygen SpeciesOxidation-ReductionOxidative stressSignal TransductionFree Radical Biology and Medicine
researchProduct

Development and description of New Nordic Diet scores across infancy and childhood in the Norwegian Mother, Father and Child Cohort Study (MoBa)

2021

Abstract In recent years, examining dietary patterns has become a more common way of investigating potential associations between diet and adverse health outcomes. The New Nordic Diet (NND) is a potentially healthy and sustainable dietary pattern characterized by foods that are locally available and traditionally consumed in the Nordic countries. The diet has been typically examined in adult populations, and less is known about compliance to the NND from infancy throughout childhood. In the current study, we therefore aimed to develop and describe child age‐specific NND scores. This study is based on the Norwegian Mother, Father and Child Cohort Study (MoBa) and uses data from the Medical B…

0301 basic medicineNew Nordic DietMaleChild agePediatricsCohort StudiesFathers0302 clinical medicinePregnancy030212 general & internal medicineNutritional diseases. Deficiency diseasesMoBachildNutrition and DieteticsNorwayObstetrics and GynecologyCognitionDietary patternPeer reviewVDP::Medisinske Fag: 700::Helsefag: 800languageOriginal ArticleFemalediet scoresCohort studyMental developmentAdultRC620-627MothersNorwegianRJ1-57003 medical and health sciencesmedicineHumansPregnancy030109 nutrition & dieteticsbusiness.industryPublic Health Environmental and Occupational HealthInfant NewbornInfantGynecology and obstetricsOriginal Articlesmedicine.diseaseMBRNlanguage.human_languageDietPediatrics Perinatology and Child HealthRG1-991businessDemographyMaternal & Child Nutrition
researchProduct

Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced/Metastatic Gastric or Gastroesophageal Ju…

2017

Abstract Purpose: Ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte–associated protein-4 interactions, enhances T-cell activation and promotes tumor immunity. This phase II study evaluated the safety and efficacy of ipilimumab monotherapy versus best supportive care (BSC) among patients with advanced/metastatic gastric or gastroesophageal junction cancer who achieved at least stable disease with first-line chemotherapy. Experimental Design: Eligible patients were randomized to ipilimumab 10 mg/kg every 3 weeks for four doses, then 10 mg/kg every 12 weeks for up to 3 years, or BSC, which could include continuation of fluoropyrimidine until progression or toxicity. The prim…

0301 basic medicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsEsophageal NeoplasmsPhases of clinical researchIpilimumabDisease-Free Survivallaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansAdverse effectAgedbusiness.industryCancerMiddle AgedInterim analysismedicine.diseaseIpilimumabSurgeryClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisFemaleEsophagogastric Junctionbusinessmedicine.drugClinical cancer research : an official journal of the American Association for Cancer Research
researchProduct

Baseline Splenic Volume as a Prognostic Biomarker of FOLFIRI Efficacy and a Surrogate Marker of MDSC Accumulation in Metastatic Colorectal Carcinoma

2020

Background: Predictive biomarkers of response to chemotherapy plus antiangiogenic for metastatic colorectal cancer (mCRC) are lacking. The objective of this study was to test the prognostic role of splenomegaly on baseline CT scan. Methods: This study is a sub-study of PRODIGE-9 study, which included 488 mCRC patients treated by 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) and bevacizumab in first line. The association between splenic volume, and PFS and OS was evaluated by univariate and multivariable Cox analyses. The relation between circulating monocytic Myeloid derived suppressor cells (mMDSC) and splenomegaly was also determined. Results: Baseline splenic volume &gt

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancermedicine.medical_treatment[SDV]Life Sciences [q-bio]MDSClcsh:RC254-282Article03 medical and health sciences0302 clinical medicineInternal medicineMedicinePrognostic biomarkerprognostic biomarkerChemotherapysplenomegalybusiness.industrySurrogate endpointmetastatic colorectal cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasedigestive system diseases3. Good healthIrinotecan030104 developmental biologyOncology030220 oncology & carcinogenesisMyeloid-derived Suppressor CellFOLFIRIcirculating monocytic myeloid derived suppressor cellsbusinessmedicine.drugCancers
researchProduct

SOLTI-1503 PROMETEO TRIAL: combination of talimogene laherparepvec with atezolizumab in early breast cancer

2020

New treatment strategies such as immune checkpoint inhibitors and oncolytic viruses are opening new possibilities in cancer therapy. Preliminary results in melanoma and other tumors showed that the combination of talimogene laherparepvec with an anti-PD-1/PD-L1 or anti-CTLA4 has greater efficacy than either therapy alone, without additional safety concerns beyond those expected for each agent. The presence of residual cancer after neoadjuvant chemotherapy in early breast cancer patients is an unmet medical need. SOLTI-1503 PROMETEO is a window of opportunity trial, which evaluates the combination of talimogene laherparepvec in combination with atezolizumab in women with operable HER2-negati…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBreast NeoplasmsHerpesvirus 1 HumanAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineBreast cancerClinical ProtocolsAtezolizumabInternal medicineClinical endpointHumansMedicineImmune Checkpoint InhibitorsTriple-negative breast cancerNeoplasm StagingOncolytic VirotherapyBiological ProductsClinical Trials as Topicbusiness.industryMelanomaGeneral MedicineImmune Checkpoint Proteinsmedicine.diseaseCombined Modality TherapyOncolytic virusClinical trial030104 developmental biologyOncologyResearch Design030220 oncology & carcinogenesisFemalebusinessTalimogene laherparepvecFuture Oncology
researchProduct

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma …

2019

Abstract Background Bevacizumab, a VEGF‐A inhibitor, in combination with chemotherapy, has proven to increase progression‐free survival (PFS) and overall survival in multiple lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor angiopoetin‐2 (Ang‐2) is associated with poor prognosis in many cancers, including mCRC. Preclinical models demonstrate improved activity when inhibiting both VEGF‐A and Ang‐2, suggesting that the dual VEGF‐A and Ang‐2 blocker vanucizumab (RO5520985 or RG‐7221) may improve clinical outcomes. This phase II trial evaluated the efficacy of vanucizumab plus modified (m)FOLFOX‐6 (folinic acid (leucovorin), fluorouracil (5‐FU) and oxaliplatin) ver…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyVEGF‐AVanucizumab20BevacizumabAngiopoetin-26Organoplatinum CompoundsColorectal cancerLeucovorinPhases of clinical researchFirst‐line metastatic colorectal cancerAntibodies Monoclonal HumanizedVEGF-ADisease-Free SurvivalMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineMetàstasiCàncer colorectalInternal medicineGastrointestinal CancerAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansNeoplasm MetastasisAngiopoetin‐2business.industryHazard ratiomedicine.diseaseColorectal cancerOxaliplatinBevacizumab030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesisCamptothecinFluorouracilbusinessColorectal NeoplasmsFirst-line metastatic colorectal cancermedicine.drug
researchProduct

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer.

2019

Immune checkpoint inhibitors radically changed the treatment of patients with non-small cell lung cancer (NSCLC). However, only one-quarter of patients benefit from these new therapies when used as monotherapy. The assessment of Program Death Ligand-1 (PD-L1) tumor expression by immunohistochemistry is used to select potential responder patients, but this not an optimal marker since it does not predict the absence of anti PD-1 efficacy. Despite this shortcoming, PD-L1 remains the gold standard biomarker in many studies and the only biomarker available for clinicians. In addition to histological markers, transcriptomic and exome analyses have revealed potential biomarkers requiring further c…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentImmune checkpoint inhibitorsReviewlcsh:RC254-282Transcriptome03 medical and health sciences0302 clinical medicineInternal medicinemedicineLung cancerExomebusiness.industrySurrogate endpointbiomarkersImmunotherapymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens030104 developmental biologyOncology030220 oncology & carcinogenesisBiomarker (medicine)ImmunohistochemistryimmunotherapyLung cancerbusinessCancers
researchProduct